The most frequent BCR-ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2 (b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the prognostic significance of the BCR-ABL1 transcript type in early chronic phase CML have been published. Overall, these studies suggest that in e14a2 patients the response to imatinib is faster and deeper. To evaluate if the BCR-ABL1 transcript type (e13a2 compared to e14a2) affect the response to imatinib and the clinical outcome in newly diagnosed adult CML patients, 559 patients enrolled in 3 prospective studies (NCT00514488, NCT00510926, observational study CML/023) were analyzed. A qualitative PCR was performed at baseline: 52% patients had a e14a2 transcript, 37% a e13a2 transcript, 11% co-expressed both transcripts and 1% had other rare transcripts. The median follow-up was 76 months (95% of the patients had at least a 5-year observation). The complete cytogenetic response rates were comparable in e14a2 and e13a2 patients. The median time to MR 3.0 (6 and 12 months) and MR 4.0 (41 and 61 months) was significantly shorter for e14a2 patients compared to e13a2 patients, with a higher cumulative probability of MR 3.0 (88% and 83%, P < .001) and MR 4.0 (67% and 52%, P 5 .001). The 7-year overall survival (90% and 83%, P 5 .017), progression-free survival (89% and 81%, P 5 .005) and failure-free survival (71% and 
| I N T R O D U C T I O N
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the BCR-ABL1 fusion gene. The BCR-ABL1 gene encodes a constitutively active tyrosine kinase, which leads to the activation of multiple signaling pathways involved in cell-cycle, adhesion and apoptosis. 1, 2 The location of the breakpoints in the ABL1
and BCR genes is variable: the breakpoint in the ABL1 gene can occur anywhere within a large area of more than 300 kb, while in the great majority of CML patients the breakpoints of BCR gene cluster within the Major Breakpoint Cluster Region (M-BCR). The M-BCR (5.8 kb) span exons e12-e16, historically named b1-b5, but the transcribed mRNA has either a e13a2 (b2a2) or a e14a2 (b3a2) junction. In 5-10% of patients, both e13a2 and e14a2 transcripts may be detected by a qualitative RT-QPCR. The fusion protein encoded by BCR-ABL1 varies in size, depending on the breakpoints: both e13a2 and e14a2 mRNAs encode a p210. [1] [2] [3] In the era of conventional chemotherapy and interferon, several studies have investigated whether the transcript type may influence the outcome of CML patients: overall, these studies failed to detect a significant and robust influence of transcript type on response and clinical outcome. [4] [5] [6] [7] Imatinib mesylate (IM, GleevecNovartis Pharma) is a 2-phenylaminopyrimidine derivative active in Philadelphia-chromosome (Ph) positive CML through a selective inhibition of the BCR-ABL1 protein. In the last decade IM has become the standard therapy of CML patients in early chronic phase (ECP). [8] [9] [10] In the IM era some studies addressing the prognostic significance of BCR-ABL1 transcript type have been published, suggesting that in e14a2 patients the response to imatinib is faster and deeper. [11] [12] [13] [14] However, the evidence is weak and mostly limited to response, particularly to molecular response. A recent analysis, conducted within the European Treatment and Outcome Study for CML (EUTOS) CML registry, did not detect survival differences (overall survival and CML-related death)
according to the transcript type, but the response and other outcome measures have not been investigated. 15 Small differences are difficult to detect, requiring large number of patients and prospective studies.
For this purpose, we have analyzed a large cohort of 559 patients who were enrolled in prospective GIMEMA studies of treatment with IM in first-line.
| M E T H O D S
Five hundred and fifty-nine patients were consecutively enrolled in 3 concurrent multicentric prospective studies of the Italian Group for ) was defined as a BCR-ABL1 transcript 0.1%, while a deep molecular response (MR 4.0 ) was defined as a BCR-ABL1 transcript 0.01% in samples with > 10 000 ABL1 copies. [22] [23] [24] [25] [26] 
| R E S U LTS

| Patients
In all the 559 patients a qualitative RT-PCR assay was performed before treatment start: 203 patients (36%) had a e13a2 transcript and 290 patients (52%) had a e14a2 transcript. All analyses and calculations were made on these 493 patients. The remaining patients had both e13a2 and e14a2 transcripts (N 5 60, 11%), or other rare transcripts (N 5 6, 1%; e1a2 and e19a2 in 2 and 4 patients, respectively). Detailed baseline characteristics according to the transcript type are presented in Table I . The baseline characteristics of patients expressing both e13a2 and e14a2 transcripts and patients with rare transcripts are presented in Supporting Information (42) 108 (37) .525
· Intermediate 74 (36) 110 (38) · High 43 (21) 72 (25) EURO score, N (%):
· Low 90 (44) 124 (43) .322
· Intermediate 101 (50) 142 (49) · High 12 (6) 24 (8) EUTOS score, N (%):
· Low 188 (93) 267 (92) .662 · High 15 (7) 23 (8) CCA Ph1 present, N (%) 7 (3) 9 (3) 1.000
Variant translocation present, N (%) 14 (7) 13 (4) .315
Derivative 9 deletions present, N (%) 27 (13) 27 (9) .188
Imatinib dose, N (%):
· 400 mg 163 (80) 208 (72) .034
· 800 mg 40 (20) 82 (28) Abbreviations: CCA Ph1, clonal chromosome abnormalities in Ph1 cells; ECOG, performance status according to the Eastern Co-operative Oncology Group (all enrolled patients were required to have ECOG performance status 0-2 at baseline); EUTOS, European Treatment and Outcome Study; Hb, hemoglobin; PLT, platelet; WBC, white blood cells.
(Ph1) cells at baseline, variant translocations or derivative 9 deletions were similar in the 2 groups. In the e14a2 group, a slightly higher proportion of patients was treated with IM 800 mg daily as initial dose (28%, compared with 20% in the e13a2 group, P 5 .034).
| Response and outcome by transcript type
The median follow-up was 76 months (range 49-94 months) and 75 months (range 7-99 months) in e13a2 and e14a2 patients, respectively (P 5 .763). The proportion of patients with an observation equal to or longer than 60 months was similar: 96% and 94% (P 5.391) in e13a2 and e14a2 patients, respectively.
The cytogenetic and molecular response rates at milestones are shown in Supporting Information at 36 months were significantly lower in patients with e13a2 transcript (52% and 67%, P 5 .001, and 20% and 30%, P 5 .013, respectively). The proportion of not evaluable patients was comparable in the 2 groups.
As far as the rapidity of response, the median time to CCyR was 6 months in both groups, with a comparable overall estimated probability of CCyR: 89% and 88% in patients with e13a2 and e14a2 transcript, P 5 .916. The patients with e13a2 transcript achieved a MMR and a MR 4.0 significantly slower than patients with e14a2 transcript: the median time to MMR was 12 and 6 months, with 83% and 88% overall estimated probability of MMR in e13a2 patients and e14a2 patients (P < .001), respectively; the median time to MR 4.0 was 61 and 41 months and the overall estimated probability of MR 4.0 was 52% and 67% in the 2 groups (P 5 .001), respectively ( Figure 1 ).
The 7-year estimated probabilities of OS (83% and 90%, P 5 .017), PFS (81% and 89%, P 5 .005) and FFS (54% and 71%, P < .001) were significantly lower in patients with e13a2 transcript (Figure 2 The patients receiving a salvage therapy (one or more tyrosine kinase inhibitors, conventional chemotherapy, allogeneic stem cell transplantation) were 64 (31%) and 71 (24%) in the e13a2 and e14a2 groups, respectively. Molecular data after treatment change were not prospectively collected, so the impact on molecular response cannot be assessed. The patients who died after progression to advanced phase were 13/64 (20%) and 13/71 (18%), respectively.
The responses and the survival probabilities of patients coexpressing the e13a2 and the e14a2 transcripts were similar to or even better than the ones of e14a2 patients (Supporting Information Figures   S1 and S2) . The response and the outcome of patients with rare transcripts are presented in Supporting Information Table SII.
| Prognostic impact of transcript type according to the initial imatinib dose
Analyzing separately the patients treated with IM 400 mg (n 5 371; e13a2 and e14a2 transcript in 163 and 208 patients, respectively) or In patients treated with standard-dose IM, the transcript type was able to predict significantly different 7-year probabilities of OS, PFS and FFS (Figure 3 ). In the high-dose IM group, the patients with e13a2
transcript had inferior PFS (71% and 86%, P 5 .039) and FFS (44% and 67%, P 5 .011), but no difference could be detected in OS (82% and 87%, P 5 .232) (Figure 3 ).
| DISCUSSION
The great majority of CML patients have a mRNA transcript with a e13a2 or a e14a2 junction. [1] [2] [3] The information on the prognostic impact of BCR-ABL1 transcript type in ECP CML patients treated frontline with IM is still limited to few studies. In 74 patients treated with IM 400 mg it was found that the CCyR rate at one year was higher in e14a2 patients than in e13a2 ones (54% vs 24%, P 5 .01).
11
In a much larger study of 1105 patients, it was found that the cumulative probability of achieving MMR and MR 4.0 was significantly higher in e14a2 patients than in e13a2 ones. 12 In 481 patients treated frontline with IM or with second generation TKIs, the CCyR and the MMR rate at several time points were higher in e14a2 patients. 13 A MR 4.0 was reported more frequently in e14a2 patients than in e13a2 ones (57% vs 27%, P 5 .003). 14 However, in only one study 13 a difference in outcome (transformation-free survival, 98% versus 91%, P 5 .01) was detectable; no differences in overall survival or other outcome measures were reported. A large analysis on 1494 European patients failed to detect survival differences, considering either deaths for any reason or CML-related deaths; responses and other outcome measures have not been analyzed. 15 In line with prior reports, we have also found that the e13a2 transcript was associated with a poorer response to IM: MMR and MR 4.0 rates were significantly lower with a significantly longer time to the first MMR and MR 4.0 . As predictable, since CCyR and MMR are the best surrogate markers of the outcome, [8] [9] [10] we also found that the e13a2 transcript was associated with a poorer outcome (OS, PFS and FFS). Moreover, the deep molecular response may predict the probability of achieving a treatment-free remission (TFR). 10 The differences between transcripts were not influenced by confounding factors: the analysis was performed considering the intention-to-treat population of each protocol, the proportion of patients lacking of cytogenetic or molecular evaluation (weighting as a negative result) was balanced between the two groups, and the relative risk distribution according to Sokal, 19 EURO, 20 and EUTOS 21 scoring systems was comparable. By multivariable analysis, the prognostic value of transcript type was even stronger than that of any other variables.
There were some differences between the two groups. In the e13a2 group there were more males, and males may have a worse prognosis; moreover, in the same group the baseline percentage of eosinophils in peripheral blood (PB) was lower, and eosinophils have been shown to have a worse prognosis. 20 More importantly, the proportion of patients treated with IM 800 mg daily as initial dose was lower in e13a2 group. High-dose IM (equal to or higher than 600 mg daily) has not been approved yet as first-line therapy of CML patients in CP. Four randomized studies comparing 400 mg versus 800 mg IM daily have been published, three for patients of any risk category [31] [32] [33] and one for high Sokal score patients only. 17 were poorer irrespective of IM dose, with the exception of OS in patients treated with high-dose (no significant difference).
The difference between e13a2 and e14a2 patients is difficult to understand and to explain. The e13a2 and e14a2 hybrid mRNA and protein differ in size by 75 bases and 25 amino acids, respectively.
These sequences are a putative site for calcium-dependent lipid
Outcome by transcript type in patients treated with standard-or high-dose imatinib. Estimates of (A) overall survival, (B) progression-free survival, (C) failure-free survival, according to the fusion transcript type in patients receiving standard-dose imatinib (patients included: 163 patients with b2a2 transcript and 208 patients with b3a2 transcript). Estimates of (D) overall survival, (E) progression-free survival, (F) failure-free survival, according to the fusion transcript type in patients receiving high-dose imatinib (patients included: 40 patients with b2a2 transcript and 82 patients with b3a2 transcript; all patients treated with high-dose imatinib had intermediate or high Sokal score). The definitions of progression and failure are detailed in the methods section binding, but the exact function is currently unknown. [1] [2] [3] With conventional chemotherapy or alpha-interferon, the BCR-ABL1 transcript type had no strong effects on the response and the outcome. [4] [5] [6] [7] Considering the selectivity of IM, the emergence of outcome differences between e13a2 and e14a2 patients suggests a potential BCR-ABL1 dependent mechanism. A higher pCrKL/CrKl ratio at diagnosis has been described in patients with a e13a2 transcript, 11 but the higher pre-treatment tyrosine kinase activity was not evaluated in a multivariate analysis including other relevant variables (ie, disease score). We may hypothesize a more efficient tyrosine kinase activity in e13a2
patients, but a systematic evaluation of the pre-treatment tyrosine kinase activity has not been accomplished in our study. Conversely, the junction sequences product of the BCR-ABL1 fusion can bind several human leukocyte antigen (HLA) class I and II molecules, and to elicit peptide-specific T-cell responses. [34] [35] [36] [37] [38] We may speculate on a putative different immunogenic ability of the e13a2 protein, which is shorter than the e14a2 one and have different junctional sequences, but no evidences supporting this hypothesis are available. Finally, the response and outcome differences between e13a2 and e14a2 patients could be due to the crystallographic structure of the BCR-ABL protein or to a different interaction between the IM molecule and the p210 protein, but clarifying data have not been published yet.
The current CML therapeutic scenario has been enriched by FDA and EMA approval of nilotinib (NIL) and dasatinib (DAS) as frontline treatment. In early CP CML, both drugs induced significantly superior rates of cytogenetic and molecular responses as compared with IM. [39] [40] [41] [42] So far, few data are available about the relationship between the BCR-ABL1 transcript type and the response to second generation TKIs: a preliminary study from the GIMEMA CML WP on 345 patients treated with NIL based regimens, despite a trend for lower response rates and inferior outcome in patients with e13a2 transcript, did not detect significant differences between e13a2 and e14a2 patients. 43 Another preliminary study from MD Anderson Cancer Center on 204 patients treated with NIL or DAS, reported a lower rate of molecular responses and a trend for inferior EFS in e13a2 patients. 44 We conclude that the e13a2 BCR-ABL1 fusion transcript affects the rate, the depth, and the speed of the response to treatment with imatinib firstline, and that including the transcript type in the calculation of the baseline risk scores may improve prognostic stratification and may help the choice of the best treatment policy. More data and a longer follow-up, are required to understand if the transcript type influences the immunologic control of residual disease, so affecting the probability of achieving a TFR.
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